Regeneron (REGN) Gets a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Regeneron, with a price target of $796.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Moderna. According to TipRanks, Flynn has an average return of 9.8% and a 56.21% success rate on recommended stocks.
In addition to Morgan Stanley, Regeneron also received a Hold from Wells Fargo’s Mohit Bansal in a report issued yesterday. However, today, Piper Sandler maintained a Buy rating on Regeneron (NASDAQ: REGN).
Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million
Read More on REGN:
Disclaimer & DisclosureReport an Issue
- Regeneron price target lowered to $921 from $925 at Bernstein
- Regeneron price target raised to $779 from $765 at RBC Capital
- Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
- Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
- Regeneron’s High-Dose Aflibercept Trial in China Nears a Key Inflection Point for Eye-Care Growth
